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Sweet child in time  
you'll see the line  
the line that's drawn between  
good and bad. 
 
Deep Purple, 1970 
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ABSTRACT 
Bronchopulmonary dysplasia (BPD) was first described in 1967 in a group of 
preterm infants as chronic inflammatory lung disease associated with arrested 
pulmonary development and supplemental oxygen needed. In humans is the 
earliest onset and probably the longest disease, and presents multifactorial origins. 
Nowadays, in preterm newborns the gold standard diagnostic methods for 
evaluating predisposition to develop BPD is airway lavage and tracheal aspirate, 
and less invasive for assessing immunological settings and biomarkers, is blood 
sample. Recently, non-invasive method based on cooling and condensing of 
exhaled breath condensate (EBC) containing several classes of compounds and 
biomarkers was proposed. Numerous researches demonstrate that in EBC high 
levels of leptin, a pro-inflammatory marker involved in lung injury, are associated 
with chronic lung disease such as asthma and COPD, but BPD was never 
evaluated. In the present study we assess EBC levels of leptin and its antagonist 
ghrelin, in preterm newborns mechanical ventilated, to identify the correlation 
with BPD development. Only few studies performed EBC on intubated preterm 
newborns to identify others markers of lung injury.  
EBC collection in first day of life showed no leptin and ghrelin concentration 
neither in BPD and nor in control group. Significant difference (p=0.002) in 
gestational age of controls compared to BPD was found, and significant difference 
(p=0.005) in the body weight of control group compared with BPD. An improved 
understanding of markers in BPD requires animal model, and the expression of 
leptin and ghrelin and their receptor were assessed in lung tissue of murine model 
of BPD obtained exposing newborns Wistar rats at high oxygen concentration for 
14 days (PN 14), and to achieve severe BPD, prolonging the exposition for 28 
days (PN28). PN14 and PN28 exposition showed a suffering look: shaggy hair, 
and general growth slowed if related with healthy controls. Architectural changes 
at PN14 confirms impaired alveolar lung development, and a reduction in the 
number and development of alveoli. Additionally, increased interstitial thickness, 
and epithelial cells with low cilia number, compared with control were found, and 
a continued exposure (PN28) showed an inflammatory and pulmonary edema 
increase. In pups statistically significant lowest values of body weight were found 
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in BPD group at PN14 (p=0.002) and at PN28 (p=0.012) compared with controls 
in air room. Different dimensions of trachea were found in two groups of 
treatment at PN14: BPD presented high trachea caliber (p=0.008) if related to 
control. In lung tissue no significant changes expression of leptin and ghrelin and 
their receptors in control group and BPD group were observed for both exposure 
periods. In conclusion, it’s possible that leptin and ghrelin may not be predictive 
markers of lung injury: probably we have collected EBC too prior with respect the 
possible BPD development, but is essential to standardize EBC collection, with 
specific attention in hardware. Another explanation is that these markers are not 
involved in BPD lung injury as well as chronic lung disease such as asthma and 
COPD. Specific role and tissue expression of leptin and ghrelin remain to be 
clarify, for this reason is necessary to further investigate and focus the attention on 
metabolic issue with other approaches like proteomic and metabolomics, to better 
understand and identify this disease that nowadays presents high incidence. 
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SOMMARIO 
La broncodisplasia (BPD) è una patologia cronica che colpisce i neonati 
pretermine e già dalla sua prima descrizione nel 1967, è stata associata ad un 
arresto dello sviluppo polmonare che necessita di ossigenoterapia. Il prelievo 
sanguigno risulta oggi giorno il metodo clinico meno invasivo per valutare il 
rischio di sviluppare BPD, tuttavia le metodiche di elezione prevedono il dosaggio 
di markers ottenuti attraverso procedure invasive quali l’aspirazione 
endotracheale ed il lavaggio bronchiale. Negli ultimi anni è stata posta particolare 
attenzione su una nuova metodica non invasiva che prevede la raccolta del 
condensato dell’aria esalata (EBC dall’acronimo Exhaled Breath Condensate). In 
un campione di EBC è possibile rilevare numerose molecole che permettono di 
valutare le condizioni respiratorie del soggetto. Tra i molteplici markers 
respiratori presenti, la leptina è un ormone recentemente associato a patologie 
croniche come l’asma e la BPCO, anche se tuttavia non è stata ancora indagata la 
possibile correlazione con la BPD. In questo studio sono stati raccolti, durante il 
primo giorno di vita, campioni di EBC in soggetti prematuri sottoposti a 
ventilazione meccanica per valutare i livelli di leptina e della sua antagonista 
metabolica, la grelina. Sono emerse differenze significative (p=0.002) nell’età 
gestazionale del gruppo di soggetti che hanno sviluppato BPD, rispetto ai soggetti 
controllo. Inoltre, è stato osservato come il peso corporeo alla nascita è nettamente 
superiore nei soggetti sani rispetto ai soggetti con BPD (p=0.005). Il dosaggio dei 
putativi markers nel campione di EBC non ha rivelato la presenza di leptina e di 
grelina, e questo esito potrebbe essere riconducibile al fatto che il campione sia 
stato raccolto troppo precocemente rispetto allo sviluppo della patologia. Un'altra 
supposizione prende in considerazione la mancanza di linee guida sulla corretta 
modalità di raccolta in pazienti intubati, causa di un probabile deterioramento del 
campione stesso. È stato quindi creato un modello animale di BPD esponendo 
ratti Wistar neonati ad alte concentrazioni di ossigeno per 14 e 28 giorni 
(rispettivamente PN14 e PN28). Al termine dell’esposizione sono stati prelevati i 
tessuti polmonari per una valutazione dell’espressione di leptina e grelina, ma 
anche in questo caso non sono emerse differenze significative nel gruppo BPD 
rispetto agli animali cresciuti in normossia, indipendentemente dalla durata 
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dell’esposizione. Tuttavia sono state riscontrate sostanziali differenze nel peso e 
nello sviluppo dell’architettura bronchiale, con particolare sofferenza nel gruppo 
con BPD comparato con gli animali controllo dove è emerso un calibro tracheale 
nettamente superiore come segno di danno respiratorio. Questi risultati 
suggeriscono come probabilmente leptina grelina non siano direttamente coinvolte 
nel danno polmonare presente nella broncodisplasia, e pertanto non possono 
essere considerati dei marcatori precoci di patologia. Tuttavia, questo studio ha 
gettato le basi per ulteriori approfondimenti nell’ambito della standardizzazione 
della raccolta del campione di EBC per evidenziare i più idonei timepoint di 
campionamento, e preservare il possibile deterioramento del campione raccolto. 
Sarà comunque necessario approfondire il putativo ruolo di leptina e grelina, 
indagando anche sugli aspetti di metabolomica e proteomica, con l’obiettivo di 
analizzare il rischio di sviluppo di una patologia cronica che tutt’oggi presenta 
ancora un’elevata incidenza. 
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INTRODUCTION 
Bronchopulmonary Dysplasia 
Bronchopulmonary dysplasia (BPD) is a chronic inflammatory lung disease 
associated with arrested pulmonary development and a need for supplemental 
oxygen. Todays the survival of preterm newborns is increasing, but infants 
frequently suffer chronic respiratory disorders, especially if had developed this 
disease. BPD was first described in 1967 by Northway and colleagues in a group 
of preterm newborns, defining developed chronic respiratory failure as sequelae of 
hyaline membrane disease/surfactant deficiency/respiratory distress syndrome 
(RDS). The results are based upon a large group of preterm infants with 
pulmonary changes resulting from mechanical ventilation and oxygen 
supplementation to treat hypoxemia (Northway et al. 1967). Few years later, it 
was highlighted how the treatment with oxygen increases production of cytotoxic 
oxygen free radicals in mice knock-out of antioxidant mechanisms, and the 
exposition to high levels of oxygen showed lung injury observable in 
morphometric analysis (Crapo et al. 1978) (Bonikos et al.1976). From the late 
1980s the National Heart Lung and Blood Institute (NLHBI) further describe the 
disease, and suggested to focus new clinical researches in this disease (Report of 
NIH, 1979). Other studies in 1985 described the pathophysiology of this disease 
and it was a lunch pad to apply the research in animal models (O’Brodovic et al. 
1985): extremely preterm newborn baboons with BPD, exposed at high 
concentration of oxygen in mechanical ventilation, showed a significant decrease 
in the number of alveoli and enlargement of airspaces that caused a reduction in 
the total lung internal surface (Coalson et al. 1995) (Coalson et al. 1999). Several 
studies explained the long-term consequences of BPD, concentrating the aim on 
the incidence of airway hyper-reactivity and then intense lung inflammation as 
disruption of normal pulmonary structures and lung fibrosis (Baraldi and 
Filippone, 2007), conditions that increase susceptibility to infection and altered 
respiratory function. Additionally, lung performance is decreased in infants with 
BPD (Bryan et al. 1973), because lung compliance is reduced and bronchial tree 
presents high airways resistance due at reduction of parenchymal elasticity 
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(Goldman et al. 1983). Although the morphologic process of lung development 
has been well described, it’s necessary to introduce the timing and ageing in lung 
growth, to better understand the onset of BPD in immature lung. It is well known 
the prenatal period consisting in embryonic stage (1-7 week) and a fetal period, 
divided in 3 stages: pseudo-ghiandolar stage (5-17 weeks), canalicular stage (16-
26 weeks) and saccular stage (24-38 weeks). The saccular period represents the 
timing for the formation of the alveoli and go on in postnatal time when the 
alveolar stage starts from 36 weeks and go on up to 2 years of age. This follows 
the micro vascular maturation and the late alveolarization (up to 5 years of age) 
(Burri, 2006). Term birth, corresponds with the alveolar phase when alveolar sacs 
evolve by alveolar ducts, conversely in preterm infants who develop BPD, are in 
the late canalicular or early saccular stage of lung development. This period is 
characterized by cells differentiation (pneumocytis type I and type II) and growth 
of the primitive alveoli and alveolar-capillary barrier (Balany and Bhandari, 
2015). In these conditions the normal lung advance programming is blocked, 
increasing the risk of occurrence of BPD. In human, in the 4th week of gestation 
the sketch of separation of trachea and esophagus is observed (Fig.1) (Herriges 
and Morrisey, 2014). 
 
Fig.1. Human lung development and BPD. (from Rivera et al. 2016) 
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Next phase is the formation of the trachea (Rawlins, 2011) that will generate the 
bronchial branch and forms all the ramifications that lead to the evolution of 
capillary network, the final large surface area and a thin capillary barrier dedicated 
to gas exchange. This lung evolution allows to transport air from external 
ambient, into the bloodstream, and exhaled out the carbon dioxide. Gas exchange 
process takes place in alveolar-capillary barrier, a thin line composed by alveolar-
vascular epithelial cells in close association, when the deoxygenated blood 
through the lung to be oxygenated (Nardiello et al. 2016). Preterm infants begin 
early pulmonary gas exchange with an inefficient alveolar and capillary network, 
and most severely affected patients remain symptomatic even in adult age. These 
infants, in the first years have a low quality of life because present recurrent 
infections with altered pulmonary function (McEvoy et al. 2014). The risk of 
infection increases if infants are affected by BPD, indeed is documented that 73% 
of these infants required at least one admission to hospital, and the 27% needed 
more than three hospitalizations (Greenough et al. 2001). In addition, they have a 
high risk of mortality after birth, and high risk to develop visual and ocular 
motility dysfunction (Chau et al. 2013) characterized by delayed visual 
maturation and subnormal visual acuity, but also visual field defects, and visual 
perceptual-cognitive problems. Infant with BPD have a high predisposition to 
develop pulmonary hypertension (Koroglu et al. 2013), and altered 
gastrointestinal motility (Broussard, 1995), although the most important disorder 
during the first two years of life of patients with BPD (Lamarche et al. 2004) is 
respiratory exacerbation caused by viral infections. Genetic factors added to 
environmental interactions (Fig.2) leading to the multifactorial origins of this 
disease that in humans is the earliest onset and probably lasts the longest, as 
showed in a recent study by Carraro and colleagues (Carraro et al. 2015) when are 
describe alteration of the lipid metabolomic profile in exhaled breath condensates 
(EBC) of adolescents with history of BPD, compared to controls.  
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Fig.2. Genetic and environmental factors and inflammation leading to the development of 
BPD. (from Balany and Bhandari, 2015) 
 
Medical advances in the care of premature infants such as use of prenatal 
corticosteroids and postnatal surfactant treatment, the avoid intubation but use of 
oxygen supplementation by continuous positive airway pressure (CPAP) (Van 
Marter et al. 2000), and use of heated high-flow nasal cannula (HHFNC) (Collins 
et al. 2013), permit relatively consistent survival of preterm infants born in the 
late canalicular, and early saccular stage of lung development. In preterm non-
human primates was observed that nasal CPAP improve the alveolar formation 
and alveolar capillary growth, if compared with mechanical ventilation (Thomson 
et al. 2004). Additionally, use of nasal low pressure high frequency ventilation 
(nasal LPHFV) shows the same improve in lung of preterm lambs and preserves 
alveolar architecture (Reyburn et al. 2008). Exposing to high tidal volumes 
increases risk factor for developing BPD in premature infants, indeed in 
mechanical ventilation, lungs present injury such as volutrauma, barotrauma, or 
atelectrauma (Hillman et al. 2011), and increase the release of pro-inflammatory 
cytokines like IL-6, IL-8, and TNFα, as well as reduced production of anti-
inflammatory cytokines like IL-10 (Carvalho et al. 2013). Also the aggressive 
treatment of symptomatic ductus arteriosus, and new insights of nutrition have 
showed a improve of outcomes. For example, nutrition both during hospitalization 
and at discharge is an important step for the correct management of health: in fact  
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rapid weight gain and crossing of centiles is not recommend, because increase the 
risk of developing hypertension, and risk to become insulin resistant (Lapillonne 
et al. 2013), especially in newborn with low weight for gestational age. According 
to nutrition, is necessary to considered that while a newborn with BPD receiving 
supplementary oxygen in delivery room, his antioxidant protection is low, then is 
more exposed to oxidative stress (Solberg et al. 2012), therefore the future 
perspectives suggest supplementation with dietary intake, or nutraceutical dietary 
supplement such as (curcuma, resveratrol and vitamin D) (Tenero et al. 2016), to 
reduce the risk to development inflammatory disorders, as has been observed in 
other lung disease such as asthma (Perrone et al. 2012). Since the classical 
characterization of BPD, defined as persistent oxygen requirement at 36 weeks’ 
gestational age, respiratory distress such as retractions, adventitious breath sound 
and tachypnea but also a changes in lung development confirmed by radiograph 
test, there have been many steps forward in neonatal medicine. The new 
knowledge on management of BPD lead to define this disease with a different 
grade of severity. In 1998 Husain and colleagues (Husain et al. 1998) described a 
“new version of BPD” highlighting the pathology found autopsy of newborn with 
BPD, and the term “new BPD” has been proposed a few years later by Jobe and 
Bancalari (Jobe and Bancalari, 2001). In the old BPD was present a large 
parenchymal fibrosis, inflammation and airway injury, instead in the new BPD is 
present a low level of fibrosis and a more uniform inflation. Moreover, in the new 
BPD smooth muscle not presents hypertrophy, no metaplasia in epithelial tissue, 
and minimal to moderate (but diffuse) alveolar septal fibrosis. In this tissue, 
alveolar development is arrested and this causing compromised lung elastic tissue 
maturation and perturbation; in new BPD we find an arrest of lung development 
instead that iatrogenic injury. Nevertheless, injuries occurring in the canalicular 
and saccular stage of bronchial development, compromise the vascularization and 
alveolarization and then make pulmonary gas exchange with an inefficient 
alveolar and capillary network. In spite of many improve in neonatal medicine 
since the first description of this disease, the incidence of BPD has nowadays not 
decline (Balany and Bhandari 2015), but to improve the management of this 
disease in 2000 a consensus categorized BPD in preterm newborn based on need 
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of oxygen supplemental: “none” (oxygen needed up to 28 days), “mild” (need 28 
days of oxygen therapy, but not at 36 weeks gestational age), “moderate” (need up 
to 30% oxygen at 36 weeks gestational age), “severe” (need for more 30% 
oxygen, with or without positive pressure ventilation or continuous positive 
pressure at 36 weeks gestational age) (Bancalari, 2001). During postnatal life the 
lung development is characterized by an increase of vascularization and develop 
of alveoli, important in the normal evolution of respiratory system (Baldwin, 
1996) (Gebb and Shannon, 2000). This growth is mediated in pathway regulated 
by the presence of specific signal peptides, cytokine and growth factors 
(Mustonen and Alitalo, 1995), and lung injury after the birth compromises the 
normal evolution, in fact in the lung of rats was observed that the inhibition of 
angiogenesis decreases alveolarization (Jakkula et al. 2000). BPD has been linked 
to the development of an inflammatory response that can occur in absence of 
clinical infection. Interactions occurs between proteins in the develop of lung, and 
with chronic lung disease of preterm birth, increase levels of pro-inflammatory 
cytokines express after alveolar injury, and characterize BPD pulmonary 
inflammation. In fact, common pro-inflammatory cytokines are the most 
extensively studied in this category of disease, because are important biomarkers 
for the prediction of adverse pulmonary outcomes in preterm infants. Several 
studies in infants showed that the bronchoalveolar lavage fluid obtained from 
newborn, presents pro-inflammatory cytokines (IL-1β, IL-6) (Kotecha et al. 1996) 
released in response to infection, but the same results was described also in 
conditions of specific inflammation. These proteins induce the release of 
inflammatory mediators and modify the adhesion molecules on endothelial cells 
by up regulation. For example, in tracheal aspirates of preterm newborn IL-1β 
induces airway epithelial cell IL-8 expression via an NF-kB dependent pathway 
(Shimotake et al. 2004) and IL-1β/Il-6 ratios are associated with risk of 
colonization with Ureaplasma urealyticum in respiratory tract (Patterson et al. 
1998). High leukotriene levels are present in lung of newborn with BPD (Cook et 
al. 1996), and also in early phases of an inflammatory response, high presence of 
TNF-α in tracheobronchial aspirate correlates with the presence of BPD compared 
with health infants (Jònsson et al. 1997). Adhesion molecules such as ICAM-1 
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(Kojima et al. 1996) (Kotecha et al. 1995) firm adhesion and migration of 
neutrophils, and L-selectin involved in the rolling of neutrophils increased 
concentrations on day 7 and on day 10 in infants with BPD (Kotecha et al. 1998). 
Moreover, the inducible PGHS-2 isoform of the enzyme involved in the 
production of prostaglandins, (autocrine and paracrine lipid mediators), are 
implicated in the lung’s response to inflammation given that pro-inflammatory 
cytokine, and other isoform constitutively expressed, PGHS-1, present in cells to 
regulate the homeostasis. PGE2 is the PGHS-2 metabolite give from fibroblasts 
and vascular endothelial cells, that are stimulated by IL-1β and TNFα and the 
presence of this substance suggests specific role in fetal inflammation (Westover 
et al. 2012). Moreover, few mature cellular elements such as granulocyte and 
macrophage are present in alveolar washes of preterm newborn, and the presence 
of this cells increase after oxygen supplementation. For example, in lamb 
underwent to mechanical oxygen ventilation, this cellular type can be considering 
as possible early markers of lung injury oxygen induced (Carlton et al. 1985), and 
if applied in preterm newborn by measurements of reduction in circulating 
granulocytes, can predicts the risk to develop BPD (Ferreira et al. 2000). In Tab.1 
are visible the expression of all markers nowadays known, and involve in this 
multifactorial disease. 
 
 
 
 
 
 
 
 
 
 
 
17 
	
Mediators of inflammation Role Expression in BPD 
Inflammatory cytokines   
Interleukins: anti-inflammatory   
IL-10 Suppresses inflammatory response by inhibiting NF-κB ↓/↔ 
IL-4, IL-13 Suppresses inflammation by inhibiting pro-inflammatory cytokine prod. ↔ 
   
Interleukins: pro-inflammatory   
IL-1, IL-6 Acute phase inflammatory response ↑ 
IL-8 (CXCL-8)  Main chemoattractant for neutrophils ↑ 
   
CC chemokines   
Monocyte chemoattractant protein (MCP)-1, 1α, 1β, 2, 
3 Recruit inflammatory cells to area of injury ↑ 
Macrophage migration inhibitory factor (MIF) Upstream regulator of innate immune response ↓ 
Tumor necrosis factor alpha (TNF-α) Enhances expression of other pro-inflammatory cytokines ↑ 
Transforming growth factor-beta 1 (TGF-β1) Pro-inflammatory ↑ 
   
Matrix proteins   
Matrix metalloproteinase-8 Disordered pulmonary remodeling after inflammation ↑ 
Matrix metalloproteinase-9 Pro-inflammatory, interferon-gamma (IFN-γ) signaling ↑ 
   
Growth factors   
Endothelin-1 Pro-inflammatory ↑ 
Vascular endothelial growth factor Pro-inflammatory ↑/↓ 
Connective tissue growth factor (CTGF) Pro-inflammatory ↑ 
Bombesin-like peptide (BLP) Increases mast cells in the lung ↑ 
Breast regression protein-39 (human analog is YKL-
40) Anti-inflammatory ↓ 
Pulmonary hepatocyte growth factor (HGF) Alveolar septation, repair ↓ 
Keratinocyte growth factor (KGF) Regulates proliferation of alveolar epithelial cells ↓ 
   
Miscellaneous   
Interferon-inducible protein 9 (IP-9 – also known as 
CXCL11) Pro-inflammatory, IFN-γ signaling ↑ 
Cyclooxygenase-2 (Cox-2) Pro-inflammatory, IFN-γ signaling ↑ 
CCAAT/enhancer-binding protein (C/EBP) Pro-inflammatory, IFN-γ signaling ↑ 
Endoglin Pro-inflammatory ↑ 
Periostin Pro-inflammatory ↑ 
Clara cell secretory protein Modulates acute pulmonary inflammation ↓ 
Parathyroid hormone-related protein (PTHrP) Alveolar growth ↓ 
Angiopoietin-2 Pro-inflammatory ↑ 
Lactoferrin Anti-inflammatory ↓ 
 
Tab.1. Markers of inflammation: function in health and level in BPD. Symbols ↑ indicates 
increase, ↓ indicates decrease and ↔ indicates no change. (from Balany and Bhandary 
2015).	
 
The effect of severity in BPD is also associated at gender and racial differences, in 
fact neonatal lung diseases may have a genetic background: for example, the 
production of hydrophilic surfactant proteins, also known as “collectins” that have 
the ability to bind and improve the control of a big group of pathogens and 
allergens, is influenced by polymorphism of intron 4 of SP-B (Surfactant Protein 
B), and specific alleles of the SP-A are associate with respiratory distress 
syndrome. Moreover, other alleles and genotypes of SP-A and SP-D (Silveyra and 
Floros, 2012) associate with severe respiratory infections in early infancy, and 
dominant mutations of SP-C are associate with different manifestations of chronic 
lung disease (Hallman and Haataja, 2003) (Marttila et al. 2003). In addition, 
growth factors, hormones, and other molecules that control lung homoeostasis 
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may influence recovery from inflammatory injury and for this reason is treated 
with nitric oxide (Truog et al. 2007), a lung protective inhaled therapy that reduce 
the pulmonary vascular resistance and improve oxygenation (Soll, 2012). Clinical 
intervention with corticosteroid therapy is applied for preventing respiratory 
disease syndrome (RDS) and in last years was the most effective therapy (Roberts 
and Dalziel, 2006) to prevent preterm delivery as shown by Liggins in a trial in 
fetal lumb in 1969: “It is suggested that this may be the result of accelerated 
appearance of surfactant activity” (Liggins, 1969). In a clinical trial was 
described as prenatal treatments with corticosteroids reduced the of 17% the 
incidence of develop RDS, improving neonatal health outcomes (Crowther et al. 
2015). Nevertheless, there are controversy in the antenatal use of corticosteroids 
(Wapner and Jobe, 2011), and in animal models (Jobe et al. 2003) is described as 
the result after treatment is not always detectable, and sometimes can presents 
adverse events. In addiction, recent guidelines recommend to treat, with antenatal 
corticosteroid therapy between 24 up to 34 weeks of gestational age, women at 
high risk to preterm delivery (Moss et al. 2002) (Practice Bulletin n.159, 2016) 
although the correct use of corticosteroids in pregnancy is unclear (Romeiko et al. 
2014) (Doyle et al. 2014). There are several animal experiments conducted on 
fetal sheep to investigate the frequency and timing of treatment, and the optimal 
dose (Jobe et al. 2007) (Jobe et al. 2009). However, the treatment is only a help 
for the infant, because the therapy with corticosteroids can prevents the develop of 
RDS in the 30% of preterm newborn, but have no effect if BPD has already been 
diagnosed (Roberts and Dalziel, 2006). BPD is frustrating for neonatologist 
affecting up 30% of very low birth weight infant. Nevertheless, all the 
mechanisms associated with the disease pathogenesis are nowadays unclear, 
because this chronic lung disease is multifactorial (Bhandari, 2014). Today BPD 
is diagnosed according to the criteria of the National Institute of Health when the 
infant required >21% oxygen for more than 28 days. (Ehrenkranz et al. 2005). 
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Use of animal models 
Over time the survival rate of patients with BPD is increased, and autopsy lung 
tissue, necessary to explore the pathogenesis, to study new treatments, or new 
intervention strategy, it’s difficult to find. For this reason, many studies are 
addressed on animal models of BPD, a field in constantly expansion because the 
characterization of pathogenic pathways to identify the disease mechanisms 
(Hilgendorff et al. 2014) in preterm newborn, and identify in-vivo pulmonary 
property are nowadays not completely clear. Several studies are needed with 
specifics animal models of BPD in rats (O’Reilly and Thèbaud, 2014) mice 
(Berger and Bhandari, 2014), in rabbits (Manzano et al. 2014) (D’Angio and 
Ryan, 2014), pre-term lambs (Albertine, 2014) and pigs (Caminita et al. 2015) 
(Arrindell et al. 2015), and finally in non-human primates (baboons) (Yoder and 
Coalson, 2014). In -vitro protocols, and microscopic imaging analysis are in 
progress, and this technology improvement, allows to better explore the lung 
development (Nardiello et al. 2016). 
 
 
 
Fig.3. Stages and gestational ages of lung development in humans and rats. C stands for 
canalicular, A stands for alveolar and P stands for postnatal day. (from O'Reilly and, 
Thébaud, 2014) 
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To better understand the develop of BPD it's Necessary to remember That there 
are some small differences between the lung development in animals and humans. 
In fact, while in sheep, baboons and humans, the saccular stage occurs in utero, in 
rodent models it begins at embryonic day 18 and the transition to the alveolar 
stage occurs at postnatal day 5, with total development at 30days after birth (Joshi 
and Kotecha, 2007). Therefore, study of the rat lung has provided to insight in the 
postnatal development stages (Kuffman et al. 1974) (Burri et al. 1974) (Kramer et 
al. 2007) (Fig.3). Another advantage on the using rats, is the duration of gestation 
(21-22 days), and the short estrus (4-5 days), but also post-partum estrus, consent 
to researcher to plan by date accurately by means of single mating. Moreover, a 
large litter size (11 in average, but depends on the strain) consents to have a 
consistent number of available pups (Burri, 1974). In animal models, is simple 
obtaining a relatively high quantity of blood sample, and after sacrifice is also 
simple collect the different organs. Also in human there are many advantages of 
using blood, first of all the presence of reference values normalization, although in 
preterm newborn sampling is a common problem, especially if are very low birth 
weight. To overcome this problem, the most promising biomarkers to be used in 
future studies, are probably non-protein molecules such as microRNAs (De Paepe 
et al. 2008) and end tidal carbon monoxide (Zhang et al. 2014), or biomarkers like 
cytokines and other molecules not only be derived from the bloodstream. 
 
 
EBC (exhaled breath condensate) 
Bronchoalveolar lavage technique (BAL) and direct aspiration of lung epithelial 
lining fluid	 in preterm newborns with BPD assess markers of lung disease, but 
this sampling is	 invasiveness and potential to cause transient inflammation. 
Additionally, BAL is difficult to repeat many times in near future, because 
increase risk of impairment of gas exchange and pneumonitis in previously 
compromised tissue (Effros et al. 2002). Non-invasive means of sampling the 
airway-lining fluid of the lungs have been purposed in last years and exhaled 
breath condensate (EBC) is a new technique by which pulmonary specimens are 
obtained to assess inflammatory markers of respiratory disease. The study of lung 
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inflammation with non-invasively procedures is better, and exhaled breath air 
contains aerosols that can be collected and analyzed for study characteristics 
capable to describe pathologic processes in the lung. This approach is based on 
previous studies carried out in the 70s afterwards summarized by Manolis in 1983 
(Manolis, 1983) when described the amount of substances present in the exhaled 
air of human breath. In the recents years several works described the correlation 
between exhaled breath condensate and disease such as asthma (Corradi et al. 
2007) (Baraldi and Carraro, 2006) and others lung disease, and for this reason 
sampling of exhaled breath condensate has been purposed as new approach for 
assessing biomarkers. As described by Hunt (Hunt, 2002), EBC contains different 
classes of aerosols and vapors, also non-volatile compounds such as lipids, ions, 
oxidation products, cytokines, adenosine, serotonin, histamine, acetylcholine, and 
surfactant. Volatile organic compounds such as ammonia, hydrogen peroxide and 
ethanol are also possible to find out. Aerosols are released during the normal 
inspiratory and expiratory phase in tidal breathing, and particular interest is due 
EBC gives a substrate by which inflammatory and biochemical components of 
lung disease can be noninvasively evaluated. EBC collection is obtained by 
cooling exhaled breath and condensing the sample into test tube kept under zero 
Celsius degrees (Hunt, 2002). Several studies on EBC biomarkers were conducted 
to assess the relationship between different classes of compounds and different 
respiratory disease such as asthma, COPD, gastroesophageal reflux disease 
(GERD), cystic fibrosis, lung cancer and many others respiratory syndrome 
(Kononikhin et al. 2106). Although in adults were described guidelines on EBC 
collection, but a standard protocol for sampling collection in mechanical 
ventilated patients is nowadays missing (Muller et al. 2006). Sample collection in 
mechanically ventilated patients is based on principles of condensation, but is 
influenced by several factors. A correct sampling requires low cooling 
temperatures and adequate sampling times (usually several minutes). Moreover, 
the sample can be contaminated and for this reason that storage and analysis 
should occur promptly at -80° C to prevent sample degradation.	 Based on this 
protocol we can safely collect the sample also in intubated patients underwent to 
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mechanical ventilation without conditioning the clinical practice: procedure is 
possible by placing the EBC device in-line with the circuit of the ventilator.  
In this study we collect EBC to assess a new putative marker of lung disease 
expressed in lung tissue of animal model of BPD. In ventilated infants the lack of 
collection methods, compared to others collaborative subjects (Baraldi et al. 2003) 
affected by asthma, is critical for early identification of preterm infants at greatest 
risk for BPD. In fact, in ventilated preterm newborns, due of this absence on the 
management of EBC collection, is difficult obtain a significant marker to relate 
with animal models. In the last few years a precious addition to clinical 
investigation, especially for metabolic changes that occur in different diseases, 
was performed. These studies are also useful for following the efficacy of therapy 
(Lal et al. 2015) and identification of specific biomarkers is also suitable for 
earlier diagnosis of BPD (Fig.4) and in the clinical management permits, to start 
specific treatments just after birth. 
 
 
Fig.4. Markers of BPD. 
 
Nowadays the prediction of BPD is evaluated with new method such as 
metabolomic (Baraldi et al. 2016), a new scientific approach that detects changing 
in metabolic profiles, leading to identify patients with more precision than clinical 
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tools available. Among models prediction of the risk to develop BPD there is a 
poor discriminative ability (Lal and Ambalavanan, 2015) and for this reason is 
necessary focus on new biomarkers development and at same time standardization 
of sample collection, for early correct finding and treatment of this disease. 
 
 
Leptin 
In 2011 was well described by Banfo and colleague that among 5-10% of 
pregnancy can present fetal growth restriction with trouble to achieve the 
genetically determined development (Bamfo and Odibo, 2011). Is well known 
how in preterm newborn exist a fetal immaturity gas exchange network, and a 
failure of the surfactant production, conditions to expose to developing respiratory 
distress syndrome, pneumonia, asphyxia and BPD (Bose et al. 2009). Despite in 
last year there are improve of medical knowledge and a more target use of 
prenatal corticosteroids and postnatal surfactant treatment, but also the avoid the 
mechanical ventilation, many countries have reported an increase of preterm birth 
rates over the past 20 years, and this general trend was recently confirmed by a 
WHO global survey (Zeitlin et al. 2013). The mechanism of lung development is 
regulated by several interactions mediated by a bi-directional signal that involve 
molecules and their receptors can have too a putative role for the treatment of fetal 
growth restriction. For example, in the group of non-traditional cytokines there 
are molecules with double role: show cytokine functions in modulating the 
immune response, but present also hormone characteristics, especially during 
metabolic processes (Ouchi et al. 2011). Among these molecules Leptin, a 16-kDa 
peptide product of the ob gene, is a cytokine-like hormone primarily secreted 
from mature adipose tissue and, in physiological conditions, its circulating levels 
correlate positively with white adipose tissue mass.	 This adipokine links 
nutritional status with neuroendocrine and immune functions and is expressed in 
fetal lung tissue, but high level expression of leptin receptors in lung and isolated 
fetal type II cells was found. In recent years, in in-vitro studies have been 
demonstrated how leptin is secreted by lipofibroblasts and its release stimulates 
type II cells to produce the surfactant. The same stimuli were highlighted in fetal 
24 
	
rat type II cells, and adult human airway epithelial cells (Torday et al. 2002). 
Leptin is also expressed (Cohen et al. 1996) from many other tissue, mammary 
epithelium (Handy et al. 2010), placenta (Leroy et al. 1996), gastric fundus, liver 
and muscle, and plays a specific role in the inflammation and immune response 
(Otero et al. 2005), because differentially increases production of TH1 cytokines 
such as IL-2, interferon-γ, TNF-α. It was also observed increasing of vascular 
endothelial growth factor (VEGF) release by airway smooth muscle, that 
promotes sub epithelial neovascularization and vascular permeability (Shin et al. 
2008). Leptin acts a pro-fibrogenic effect in primary human lung fibroblasts 
augmenting the transcriptional activity of TGF-β1 via suppression of the 
antifibrotic activity of PPARγ, and this observation is confirmed with animal 
model of leptin-deficient mice: these animals were resistant to the development of 
airways lung injury (Jain et al. 2011). Leptin is also involved in the regulation 
mechanisms of the T cell proliferation and activation, natural killer cell function 
(Matarese et al. 2005), angiogenesis promotion and monocytes and macrophages 
system recruitment, playing significant role in airway inflammation. The diseases 
involved in these processes are acute lung injury (Ubags et al. 2014), but also 
chronic disease COPD (Chronic Obstructive Pulmonary Disease) (Kim, 2014) and 
asthma (Vernooy et al. 2013) (Ali Assad and Sood, 2012). Leptin presents a 
pleitropic effect (Paraskevas et al. 2006) contributing to control of the body 
weight by influencing appetite and energy expenditure, and acting on the hunger 
centre of the hypothalamus and brown adipose tissue (Fig.5) (Mancuso et al. 
1985) (Campfield et al. 1995). Focusing the attention on other role of leptin is it’s 
possible describe its action as a lypostate: when the amount of fats stored in the 
adipocytes increases, leptin is released into the bloodstream, a negative feedback 
signal for the hypothalamus. With this message of metabolic information is 
highlights that energy reserves are sufficient, and hypothalamus releases 
anorexigenics peptide and suppressing orexigenic factors (de Luis et al. 2009). 
Studies in humans and in animal models have been demonstrated that low levels 
of leptin are associated with obesity (Fig.5) (Montague et al. 1997) (O’Donnell et 
al. 2000) (Wabitsch et al. 2015). For this reasons it has been hypothesized a 
possible leptin resistance condition in obese patients because high 
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concentrations in obese with normal weight subjects were found (Auwerx and 
Staels, 1998). Leptin exerts its biological actions by binding to its receptor (Ob-
R), a member of class I cytokine receptor superfamily, presents in six isoforms 
(Matarese et al. 2005): a soluble isoform, with short cytoplasmic domains. Other 
isoforms, the long isoforms, are found in almost tissues and which seems to be the 
only isoform capable of transducing the leptin signal in many tissues including 
brain, placenta, hematopoietic cells, liver, heart and lung (Bruno et al. 2005). 
Leptin binds to short and long forms of its receptors, which are generated by 
alternative splicing of leptin receptor gene (Lee et al. 1996). This link transmits 
extracellular signals through the janus kinase (JAK) and signal transducer, and 
activator of transcription (STAT) signaling pathway (Fruhbeck, 2006). Most 
immune cell types express Ob-R at their surface, which suggests a role for leptin 
in immune responses. In the last years, many studies have showed the potential 
role of leptin in lung development and remodeling (Vernooy et al. 2013), 
suggesting an evident role of this hormone in pulmonary homeostasis. For 
example, animal models show how leptin contributes to the regulation of 
respiratory lung function, acting as a stimulant factor of ventilation. In an obese 
mouse model (ob/ob mouse) respiratory abnormalities including tachypnea, 
decrease lung compliance and aberrant respiratory muscle are common and 
prolonged treatment with leptin attenuates respiratory abnormalities, suggesting a 
role for leptin also as a neuro-humoral modulator of central respiration 
(Tankersley et al. 1998). Several studies have been conducted regarding the leptin 
impact on inflammatory lung disease, and reported a relationship between serum 
leptin levels and the presence of chronic lung disease like asthma. Serum leptin 
levels in asthmatic children, especially males, were higher than healthy control, 
despite no difference in BMI (body mass index) (Guler et al. 2004). Based on the 
association between leptin and systemic inflammation, it has been hypothesized 
also a potential link between obesity and chronic lung disease such as asthma 
(Antonopoulou et al. 2008). In human, obese subjects showed high leptin levels in 
bronchoalveolar lavage (BAL) compared to lean subjects and these results are 
supported by a positive correlation with BMI, lung function, TNF-α in BAL, 
nitrates, 8-isoprostanes. Moreover, it’s possible observe values increasing if 
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subjects were affected by asthma (Lessard et al. 2011) (Holguin et al. 2011) 
(Lugogo et al. 2012). In a recent paper (submitted to reviewers) we demonstrate a 
statistically significant difference between serum levels of leptin in obese children 
with asthma compared with controls non-obese and not affected by asthma 
(healthy children). The same results were found in the leptin levels in exhaled 
breath condensate (EBC). These data suggest how leptin can be a new marker of 
lung inflammation to evaluate the outcome of chronic disease. Currently while 
many investigators reported a possible link between several diseases in the lung 
and systemic levels of leptin, describing leptin and its receptor, the relationship 
with infants affected by BPD has not yet been evaluated. A putative link between 
BPD and serum leptin remains nowadays unclear because no data are available on 
the potential presence of leptin in epithelial lung fluid. Further studies are needed 
to found the relationship in systemic inflammation of the lung and evaluate as 
specific target the BPD. 
 
 
Ghrelin 
Among non-traditional cytokine it’s possible citing ghrelin, a unique 28 amino 
acid peptide purified form the stomach of rat (Kojima et al. 1999) that acts as 
endogenous ligand for the growth hormone secretagogue receptor (GHS-R) and 
has a strong effect on GH (growth hormone) regulation (Sun et al. 2004). Ghrelin 
is mainly produced by a subset of stomach cells and by the hypothalamus, 
pituitary, and other tissues, and after transcription is necessary a post translational 
modification consisting in the acylation of the hydroxyl group of the serine 3 in 
the endoplasmic reticulum. This peptide is major express in digestive system, but 
low levels were found in nervous system, in the pituitary but also in other tissue 
(Gnanapavan et al. 2002), including lung (Ghelardoni et al. 2006). Subsequent 
studies have demonstrated the wide distribution of ghrelin and its receptor, and 
this proposes potentially exhibit of multiple biological activities such as 
myocardial injury, neurogenesis, bone metabolism, reproductive function, 
memory and sleep (Nerula and de Boisblanc, 2015). Moreover, has been found 
that ghrelin acts in modulation of glucose and lipid metabolism, appetite control, 
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and food intake (Mokrosiński and Holst, 2010) and has been hypothesized a 
promising therapeutic target for cognitive dysfunction, but also metabolic 
syndrome and such as obesity and type 2 diabetes mellitus (Cong et al. 2010). 
Most of the research focuses on the role of ghrelin in food intake and its related 
endocrine functions. However, given the wide distribution of GHS-R on several 
immune cell subsets, it was evaluated the effect on the immunological system 
(Dixit et al. 2004) (Dixit and Taub et al. 2005). There is a specific relation 
between immunological system and food intake: the cellular adaptive response is 
dependent from energy supply in the cells. For example, an event like the loss of 
appetite can be a predictive cause of illness or general injury (Kelley et al. 2003), 
and is well known how plasma ghrelin concentration increase before (Cummings 
et al. 2001)	 and decrease after (Ghelardoni et al. 2006) every meal (Fig.5). The 
central nervous system controls food intake and energy homeostasis by releasing 
inflammatory cytokine (Hart,1988). Ghrelin inhibits the production of 
inflammatory cytokines in BALB/C mice after intraperitoneal injection of LPS 
endotoxin shock (Dixit et al. 2004). 
	
Fig. 5. Ghrelin and leptin exert mutually antagonist regulatory effects on metabolism and 
inflammation. (from Narula and de Boisblanc, 2005) 
 
Moreover, during inflammation ghrelin and its receptor are present in neutrophils, 
lymphocytes and macrophages and their expression is regulated during acute and 
chronic injury. The influence on the immune system it was recently demonstrated 
in vivo and in vitro (Li et al. 2015). Ghrelin can also antagonize leptin, a pro 
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inflammatory protein that promote the cytokine production, in direction of pro-
inflammatory pathway. These findings suggest a specific role in the homeostasis 
regulation as well as in the setting of immune system (Fig.5) (Narula and de 
Boisblanc, 2015). Several research conducted in animal models have 
demonstrated the protective effect of ghrelin on acute lung injury on improving 
pulmonary pathological damage, permeability, mechanics and gas exchange (Li et 
al. 2016). Over the last few years have been conducted clinical trials (Miki et al. 
2012) in witch was administered ghrelin in human to assessed the effect in 
chronic lung injury like COPD and bronchiectasis (Kodama et al. 2008) 
(Matsumoto et al. 2015). In infants, especially in the newborns, the role of ghrelin 
has been evaluated to study the nutritional status (Andreas et al. 2016), the 
oxidative stress (Luo et al. 2015), but no studies assessed the possible relation 
between ghrelin and the lung injury presents in preterm infants and in infants with 
BPD. 
 
 
Aim 
The aim of this research is the evaluation of level of two markers in the airways. 
In particular, to avoid further stress in the management of care, or going against 
the clinical practice and ethical principle, this research has focused on the 
evaluation of leptin in airways with non-invasive technique. Among the sampling 
techniques the aim of the present study is evaluate the levels of leptin and ghrelin 
in EBC of preterm newborn underwent to mechanical ventilation. The hyperoxia-
induced neonatal lung injury model is widely used as murine model of BPD to 
assess pathological hallmarks and tissue injury. In this study the tissue expression 
of leptin and ghrelin was not assessed in human, because is no ethical perform a 
biopsy in children without needed clinical, and so we have evaluated the 
expression of these markers in a lung tissue of animal model of BPD exposed to 
high oxygen concentration for 14 days and 28 days. 
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METHODS 
Study design 
Preterm newborn 
After birth, preterm newborns were underwent to mechanical ventilation and 
oxygen supplementation, according to medical vital parameters and only for the 
clinical stabilization. Exhaled breath condensate was collected, after parents had 
signed the informed consent, and however without interpose in any way with 
clinical practice and on child health.  
 
Animal model 
At the birth Wistar pups and mother were exposed to continuous 60% of oxygen 
concentration for 14 postnatal days (PN14), to induce BPD according to O’Reilly 
(O’Reilly and Thébaud, 2014). The other group was exposed for 28 days (PN28) 
to continuous 60% of oxygen concentration. The control group was maintained in 
room air concentration during all experiments (Fig. 6). 
 
 Birth PN14 PN28 
Control group room air  
BPD group 60% O2  
Control group room air 
BPD group 60% O2 
 
Fig. 6. Treatment schedule of controls and BPD. 
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Sampling of EBC in preterm newborn 
This clinical study was designed and shall be implemented and reported in 
accordance with the Guidelines for Good Clinical Practice, an international ethical 
and scientific quality standard for designing, conducting, recording, and reporting 
studies that involve the participation of human subjects. Were applied local 
regulations (including European Directive), and the ethical principles laid down in 
the Declaration of Helsinki. Participation of patients is based on the Italian 
regulations and local Ethic Committee requirements. This study is approved by 
local Independent Ethical Committee with number CESC37. We have enrolled 14 
mechanically ventilated patients (8 with BPD and 6 with acute respiratory distress 
syndrome) admitted to Neonatal Intensive Care Unit of Azienda Ospedaliera 
Universitaria Integrata, University of Verona, Italy. The diagnosis of BPD was 
defined as oxygen dependence for at least 28 postnatal days for infants 32 weeks 
or greater postmenstrual age or oxygen dependence at 36 weeks postmenstrual 
age for infants born before 32 weeks according to Jobe (Jobe and Bancalari, 
2001). Control group of healthy newborns was not included because, to collect 
EBC sample with the suggested method, is necessary mechanical ventilation. 
 
Inclusion criteria 
• Gestational age <33 weeks, or weight at birth ≤1500g need for mechanical 
ventilation. 
• Signed the informed consent from parents. 
 
Exclusion criteria 
• Subjects with major surgery just after the birth. 
• Subjects with major congenital anomalies (e.g. arteriovenous shunt), 
congenital heart disease or known cytogenetic disorders (e.g. Down’s 
syndrome). Open ductus arteriosus and open foramen ovale are not 
exclusionary anomalies. 
• Subject has known or suspected immunodeficiency, such as known human 
immunodeficiency virus (HIV) infection. 
• Subject has suspected hepatitis B or C infection. 
31 
	
• The subject’s legally acceptable representative, i.e., parents or legal 
guardian/caregiver, is not able to communicate reliably with the clinicians 
involved in this study. 
• Withdrawal of informed consent by parents. 
 
Newborns group were comparable for gender, body weight at birth and ethnicity. 
Patient’s characteristics are shown in Tab.2. 
 
Exhaled breath condensate was collected in the supplemental oxygen ventilator 
circuit after clinical stabilization. To assess the reproducibility of the EBC the 
sample was collected for 3 hours just after positioning the ventilation circuit. The 
volume collected is depending by the flow stream, and after collection all samples 
were stored in polypropylene (Eppendorf) tubes at -80°C.In this time were 
collected 3 different samples of EBC to assess the reproducibility. All neonates 
were mechanically ventilated with Babylog 8000Plus Ventilator (Drager 
Williamson Ct. Louisville, Kentucky 40223 USA) and were monitored in 
continuous oxygen saturation, respiratory rate, tidal volume, heart rate, and 
electrocardiography (data not cited). The circuit used was RT225 (Fisher & Paikel 
Healthcare Ltd, New Zeland). Sample integrity was guaranteed by maintaining of 
EBC cooling trap in ice bath, applied to the container dedicated to EBC collection 
as illustrated by Hunt (Hunt, 2002).  
 
 
Leptin measurement 
The Enzyme Linked Immuno Sorbent Assay (ELISA) kit (BioVendor Human 
Leptin ELISA) was used to measure leptin concentrations in EBC sample. The 
lower detection limit of the assay was 1 ng/ml and the sensitivity was 0.2 ng/ml. 
This technique involves the use of an indicator molecule coupled covalently with 
an enzyme, which converts the colorless substrate into a colored product, so that it 
can be detected by a spectrophotometer. The scheme is the following: use of a 
polystyrene plate with 96 wells coated with the primary antibody monoclonal anti 
human leptin; construction of a standard curve using serial dilutions of a known 
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concentration of the antigen and the specimens were added of condensate and 
serum concentration in unknown; addition of secondary antibody conjugated to 
peroxidase, and finally addition of the TMB detector substrate (3,3', 5,5'-
tetramethylbenzidine). The substrate in the presence of HRP complex (horseradish 
peroxidase complex) develops a blue color. The reaction was quenched adding 
acid solution. The intensity of staining is proportional to the amount of specific 
antibody present in the sample. The plate is then read in a spectrophotometer at 
λ=450nm. 
 
 
Ghrelin measurements 
A commercial ELISA kit (EZGRT-89K; Millipore) was used to measure ghrelin 
concentrations in EBC sample. The lower detection limit of the assay was 165.62 
pg/ml and the scheme work is the same as previously described for leptin 
detection. The absorbance was read in a spectrophotometer at wavelength 450 and 
590 nm. 
 
 
Animal model  
The study was approved from Technical Ethical Committee of the University of 
Verona for experimental animal. Female rats were purchased from Charles River 
Laboratories Italia s.r.l, Calco, Lecco, Italy. Animals were acclimatized to the 
departmental animal facilities for at least 1 week before to program the mating. 
They were kept in individual cages with sawdust and free access to food and 
water; a temperature-controlled environment (21–23 °C) and humidity of 50% on 
a 12 hours’ light–dark cycle with light ON at 8:00AM. All animals were handled 
in accordance with the Helsinki Declaration and recommendation for animal 
experimentation established of the Italian Public Health Authorities. The study 
was conducted on Wistar female rats weighing 250 g and pregnancies were dated 
accurately by means of single mating. At the term of gestation Wistar females and 
pups were divided in 2 groups: control group placed in acrylic chambers 
(Tecniplast mod 1290D, Buguggiate, VA, Italy) in room air, and BPD group 
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according with O’Reilly (O’Reilly and Thébaud, 2014). The BPD group 
(exposed) was placed in acrylic chambers (Tecniplast mod 1290D, Buguggiate, 
VA, Italy) contained in the hyperoxic setup (BioSpherix, Animal Chamber A-
30274-P, Redfield NY). Except for the concentration of oxygen created by 
introducing a continuous 60% oxygen flow constantly monitored (BioSperix, 
OxiCycler model A84XOV, Redfield, NY), in the BPD group the ambient 
conditions are the same than control as previously described. To reduce the 
possible confounders in both groups, confinement was briefly stopped every 6 
days just the necessary time for changing of cage with partial new sawdust, and 
restored food and water. The “gentle handling” procedure is based on a direct 
interaction with the experimenter, who keeps the animal under control and 
provided to change the cages. All efforts were made to minimize animal suffering 
and to keep the lowest number of animals used. The study was conducted on 
Wistar rats in hyperoxic chamber (n=14) and in room air (n=10). In the end of 
experiment all Wistar pups were anesthetized with an overdose of isoflurane. 
Body weight was recorded at the time of the death. Thorax was opened and lungs 
were removed in toto, then fixed in buffered formalin and embedded in paraffin, 
then sectioned using a microtome at 5µm and stained, for histological evaluation 
with hematoxylin and eosin (H&E). 
 
 
Histological examination 
The chest of the rats was opened and trachea, bronchial tree and lungs were 
carefully removed in toto and fixed in 4% paraformaldehyde, then dehydrated in 
rising gradient ethanol, vitrified in xylene and embedded in paraffin. The paraffin-
embedded sections (5µm-thick) were stained with H&E. Morphological changes 
were evaluated (×40 magnification) using an optical microscope Olympus BX51 
integrated with digital camera (JVC CCDKY-F58) equipped with the image 
analysis digital system Image-Pro Plus 7.0 (Media Cybernetics, Silver Spring, 
MD, USA).  
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Immunohistochemistry (Merigo et al. 2016) 
In this study were selected the following primary antibodies: rabbit anti-ghrelin 
(Phoenix Pharmaceuticals Inc., Burlingame, CA, USA, cat #H-031-31); rabbit 
anti-ghrelin receptor (-GRLN-R Abcam, Cambridge, UK, cat #ab85104); rabbit 
anti-leptin (Abcam, Cambridge UK, ab3583); rabbit anti-leptin receptor (Abcam, 
Cambridge, UK, ab5593). Peroxidase-immunohistochemistry was performed as 
described by Merigo et al 2011. Sections were treated with blocking solution 
(0.3% Triton X-100, 1% bovine serum albumin (BSA), and 1% swine serum 0.1M 
phosphate buffered saline (PBS) for 1 hour. Previously the endogenous 
peroxidase was quenched for 20 min in a peroxidase blocking solution (DAKO, 
Milan, Italy), then washing in PBS buffer pH 7.5. Sections were incubated 
overnight with primary antibodies diluted in blocking solution, then washed and 
reacted for 1h with diluted 1:400 biotinylated swine anti-rabbit immunoglobulins 
(DAKO). The immunoreaction was detected using a Vectastain ELITE ABC kit 
(Vector, Burlingame, CA, USA) and then visualized with 3.3-diaminobenzidine 
tetrahydrochloride (DAKO) for 5-10 min. Moreover, control sections were 
prepared by pre-absorbing the primary antibodies with the corresponding peptide 
(5 µg/1 mL of antibody; Ghrelin peptide, Phoenix Pharmaceuticals Inc.; Ghrelin 
Receptor peptide, Abcam) or by omitting the primary antibody. Sections were 
observed using an optical microscope Olympus BX51 integrated with digital 
camera (JVC CCDKY-F58) equipped with the image analysis digital system 
Image-Pro Plus 7.0 (Media Cybernetics, Silver Spring, MD, USA). 
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RESULTS 
Statistical analysis 
All data were expressed as median and IQR (interquartile range). Comparisons 
between 2 groups analysis were made using Mann-Whitney U test for non-
parametric test. Statistical analysis was carried out GraphPad Prism v5.00 for 
Windows (GraphPad Software, San Diego, CA, USA). In all cases was considered 
significant a value of p<0.05. 
 
 
Preterm newborn 
Characteristics of patients 
The characteristics of patients are showed in Tab.2. All 14 patients had been 
underwent to mechanical ventilation after birth and all had received the treatment 
with surfactant. All moms were nonsmokers, and passive tobacco smoke non-
exposed. The difference in mode of delivery was no significant as well as other 
birth characteristics reported in Tab.2. 
 
 Non-BPD BPD p-value 
Number of patients 6 8 / 
Gender   / 
    male 2 4 / 
    female 4 4 / 
Mode of delivery   / 
    cesarean section  2 4 / 
    vaginal 4 4 / 
Maternal pren. corticosteroids 3 2 / 
Maternal antibiotic exposure 1 1 / 
Surfactant treatment 6 8 / 
*Apgar at 1 min. 5.5 (3.5-6) 4 (3-6) n.s. 
*Apgar at 5 min. 7.5 (6.3-8) 8 (6-8) n.s. 
*Gestational age, weeks 29.4 (28.3-30.9) 24.8 (24.6-26.6) 0.002 
*Body weight at birth, g 1275 (1000-1646) 755.0 (700-840) 0.005 
    
Tab.2. Demographical and clinical data on newborns. *Data are expressed as median and 
(range).  
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As can be seen in Tab.2 a significant difference (p=0.002) was found in 
gestational age. In particular, in the control group the median of weeks was 29.4 
(IQR 28.3-30.9) if compared with BPD group that shows a median of 24.8 (IQR 
24.6-26.6) weeks of gestational age. At birth a significant difference (p=0.005) in 
body weight in control group 1275g (IQR 1000-1646g) compared with BPD 
group 755.0g (IQR 700-840g) was found. BPD group is classified according to 
Jobe (Jobe and Bancalari, 2001): after 28 days of oxygen dependence for at least 
28 postnatal days for infants 32 weeks or greater postmenstrual age, or oxygen 
dependence at 36 weeks postmenstrual age for infants born before 32 weeks. For 
this study, body weights were not registered longitudinally at the same time point 
for all patients during the admission to intensive care, and for this reason we 
prefer to don’t cite this data at discharge and when oxygen treatment was stopped. 
 
 
EBC leptin and ghrelin 
Pulmonary levels of leptin in EBC of mechanical ventilated patients were not 
found with ELISA commercial kit previously described. Three test were repeated 
in three different back-up samples stored at -80°C. In EBC was assessed the levels 
of ghrelin with ELISA kit previously described. After three repeated test on back-
up (stored at -80°C) were found no ghrelin concentration EBC sample. Levels of 
leptin and ghrelin were not found neither BPD group and nor in controls group. 
 
 
Animal model of BPD 
Mortality index 
The study was conducted on Wistar rats in hyperoxic chamber (n=14) and in room 
air (n=10). 71.4% of neonatal rats exposed to hyperoxia survive, with the majority 
of deaths occurring between 2 and 8 days after birth. These finding have been that 
group continuously expose to 60% of oxygen presents a high rate of mortality at 
time PN14 compared with control keep in room air, from 14 pups (100%) to 10 
pups (71.4%). Prolonged neonatal exposure to high oxygen concentration presents 
equal index of mortality at PN28 (Fig.7). 
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Fig.7. Mortality index in animal model of BPD. 
 
Body weight 
Maternal body weight was assessed at the time of the mating and at spontaneous 
delivery. Moreover, the weight was assessed after 14 and 28 days of exposition at 
high concentration of oxygen and was observed a body weight loss, suggesting a 
massive exposition at oxidative stress. No difference in body weight was observed 
in maternal body of control group. In the litter, statistically significant lowest 
values of body weight were found in BPD group (19.53g; IQR 18.63-21.89) after 
14 days of exposure of 60% oxygen concentration if compare with controls in air 
room (28.02g; IQR 25.75-29.45) p=0.002 (Fig.8a). 
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Fig.8a. Body weight in animal model of BPD compared with controls at PN14. 
 
A statistically significant difference was found in BPD group exposed at 60% 
oxygen for 28 days compared with control group. In particular, BPD group shows 
a body weight 61.53g (40.95-80.26) compared with group kept in air room 128.6g 
(123.1-131.9) p=0.012 (Fig.8b). 
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Fig.8b. Body weight in animal model of BPD compared with controls at PN28. 
 
Body characteristics 
At PN14 hyperoxic rats showed a suffering look, with shaggy hair, and general 
growth slowed if compared with healthy controls kept in air room (Fig.9). Critical 
differences in motor activity and neurological status were not found in two 
groups. 
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Fig.9a. General growth in healthy control and BPD model at PN14. 
 
Same results in body development were found at PN28. In particular, control 
group presents a normal shiny hair, without sign of suffering. Conversely, the 
hyperoxic group presented a hispid and rugged hair (Fig.9b). 
 
 
Fig.9b. General growth in healthy control and BPD model at PN28. 
 
All animals presented a normal development of whiskers and no other 
morphological abnormalities were found. 
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Histology and immunohistochemistry  
Different dimensions of trachea were found in two group of treatment during 
tissue collection. H&E stained tissue section were used to evaluate the dimensions 
of trachea in two groups. In particular, the caliber in the control group presents 
normal cavity with a thin trachea wall compared with BPD model, where is 
showed a large lumen and a thick wall. As can be seen, tracheal mucosa presents 
normal tract but also an increased thickness of lamina propria (Fig.10).  
	
	 	 	
Fig.10. Section of trachea stained with H&E in Wistar control group (room air) and 
Wistar BPD group at PN14; (40X).		
	
In control group at PN14 we found a significant difference in median values of 
trachea caliber. For each rat in the experiment we performed 5 measures on 
trachea caliber. Control group presented value of 0.75mm (IQR.0.70-0.76), 
instead in the BPD group presented a median value of 1.67mm (IQR 1.52-1.74) 
with significant difference (p=0.008) (Fig.11). 
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Fig.11. Caliber of trachea Wistar control group (room air) and Wistar BPD group at 
PN14;  
 
Architectural changes at PN14 shows impaired alveolar lung development. In 
particular, a reduction in the number of alveoli and a simplification of structure in 
acinar development were found. Specimens stained with H&E show an increased 
interstitial thickness, and epithelial cells reported a low number of cilia if 
compared with control (data no showed). A continued exposure to high oxygen 
concentration (PN28) shows increasing in inflammatory and pulmonary edema 
response. 
 
 
Leptin and ghrelin expression 
Leptin expression was observed in control and exposed groups to compare the 
results. The experiment was conducted as described by Merigo (Merigo et al. 
2016). In this case we don’t apply a co-localization technique using 
immunofluorescence. In BPD rats’ leptin immunoreactivity was similar than 
control rats (Fig.12a). Leptin receptor expression were observed mainly in in 
apical surface of cell but a minimal expression was found also in the cytoplasmic 
vesicles (Fig.12b) but there are no significant differences between control group 
and BPD group. Moreover, with the continuous exposition to high oxygen 
concentration in the BPD group at PN28 can be seen the worsening in the tissue 
architecture, but difference in leptin expression, in comparison two groups, were 
the same those observed at PN14 (Fig.12c). 
42 
	
  
Fig.12a. Leptin expression in free floating sections at PN28 (20x).  
 
 
  
Fig.12c. Leptin receptor expression at PN28 in control group and in BPD group (100x). 
There are no different expressions in two group. Apical expression and minimal 
cytoplasmic expression in lung tissue was found.  
 
  
Fig.12b. Leptin receptor expression at PN28 in control group and in BPD group (10x). 
 
 
Ghrelin expression was observed in control and exposed groups to compare the 
results. The experiment was conducted as described by Merigo (Merigo et al. 
2016). Also in this case we don’t apply the immunofluorescence technique to 
Control BPD 
Control BPD 
Control BPD 
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assess the co-localization. Lung section of BPD rats show ghrelin 
immunoreactivity similar than control rats (Fig.13a and b) in time point PN14 but 
also in PN28. Ghrelin receptor shows the same expression comparing control 
group and BPD group (data no showed). 
 
 
  
Fig.13a. Ghrelin expression in lung of control group and BPD group (Free floating 10X 
 
  
Fig.13b. Ghrelin expression in lung of control group and BPD group (Free floating 60X). 
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DISCUSSION 
Bronchopulmonary dysplasia is the most common chronic lung disease in infants 
associated with arrested pulmonary development. Nowadays BPD remains the 
most common complication of preterm newborn with important impact on 
mortality and morbidity. These infants are the principal division of intensive care 
units, and an important target is the early diagnosis and precise clinical 
management strategies to improve outcome of disease. BPD was first described in 
1967 by Northway and colleagues in a group of preterm infants resulting from 
high oxygen concentration and mechanical ventilation (Northway et al. 1967). In 
particular, postmortem acute lung injury, edema, extensive airway epithelial 
metaplasia, pulmonary fibrosis, and airway and vascular smooth muscle 
hyperplasia were found. Oxygen therapy plays an important role in modern 
neonatal intensive care, improving survival of preterm newborn with respiratory 
disorders. Although mechanical ventilation and oxygen supplementation found 
large use, they induce lung injury with a worsening of outcome, increasing the 
risk to develop a neonatal lung disease, like BPD. Improve medical care of 
premature infants with new management, such as the use of prenatal 
corticosteroids and postnatal surfactant replacement, the gentle ventilation 
modalities by CPAP and HHFNC, but also improved nutrition, now permit 
significant transition from “old BPD” described in 1967 to “new BPD” (Jobe and 
Bancalari, 2001) (Husain et al. 1998). New BPD was described in 2001 and 
compared to the old BPD presents less prominent inflammation, no hypertrophy 
in smooth muscle, no metaplasia in epithelial tissue, and minimal to moderate (but 
diffuse) alveolar septal fibrosis occurs mostly in extremely and/or in very low 
birth weight. Despite of many improve in neonatal medicine since the first 
description, incidence of BPD not decline showing high impact on 28 weeks of 
gestational age newborns (Balany and Bancalari, 2015). Infants with BPD present 
a high risk to develop respiratory infection with repercussion on pulmonary 
function that requires prolonged and recurrent hospitalization in the first years of 
life (McEvoy et al. 2014). In the lung development, the saccular period represents 
the timing for the formation of alveoli and go on in postnatal time from 36weeks 
of gestational age to 2 years of age, characterized by an increase of micro vascular 
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maturation and late develop of alveoli (up to 5 years of age) important for the 
ultimate the evolution of respiratory system (Burri, 2006). In term birth children 
the alveolar stage is normally developed, but in preterm infants, in the late 
canalicular or early saccular stage, the degree of lung immaturity increasing the 
risk of occurrence of BPD. Diagnostic biomarkers for predicting early BPD risk 
and standardized clinical research is needed, to better characterize the long term 
outcomes, and risk to develop other chronic lung disease such as asthma and 
COPD. Is well known the quantification of airway inflammation, including 
assessment of biomarkers with BAL and tracheal lavage, but these procedures are 
invasive, not suitable for routine use in clinical research, and potential cause of 
transient inflammation. Non-invasive technique based on evaluation of markers of 
lung inflammation or predictive of lung injury are significant for neonatologists 
during management of preterm infant in intensive care. In recent years EBC 
technique, based on cooling and condensing of exhaled breath air into test tube, 
was well described and has found a large use because non-invasive and safe. 
Moreover, the sample collection is very easy to perform even in children, offering 
various biomarkers to evaluate the lung inflammation. Accordingly, several 
studies have assessed respiratory lung disease looking for EBC biomarker such as, 
isprostane, leukotrienes, MMP, GSH, ADMA and others. Nevertheless, only few 
studies assessed EBC to evaluate the risk to develop BPD, especially from 
mechanical ventilated preterm newborn. For example, it has been used EBC to 
test levels of hydrogen peroxide and the levels of GSH, suggesting as these 
molecules may be potential parameters to define chronic lung disease 
(Kononikhin et al. 2016). Among markers of inflammation in EBC the leptin, a 
hormone expressed in a variety of tissues (Cohen et al. 1996) such as 
hypothalamus, placenta, and lung, and is implicated in energy homeostasis with 
neuroendocrine and immune functions, was found. In our experience (submitted 
to reviewers) asthmatic children present high level of EBC leptin compared with 
healthy controls, and this data confirm how leptin is a marker of lung 
inflammation. Also several studies have been conducted on leptin existence in 
inflammatory lung disease, and reported a relationship between serum leptin 
levels and the presence of chronic lung disease like asthma (Antonopoulou et al. 
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2008) (Ubags et al. 2014). BPD has been linked to the development of an 
inflammatory response that can occur in absence of clinical infection: an increase 
of pro-inflammatory cytokines values was found in tracheobronchial aspirates 
from premature infants TNFα, IL-8, IL-1β and IL-6, have been shown to correlate 
with increased risk of BPD (Kotecha et al. 1996) (Jònsson et al. 1997). Various 
studies mentioned the role of leptin in the inflammation, for example acute lung 
injury like pneumonia (Ubags et al. 2014) or chronic lung inflammation such as 
COPD (Kim, 2014) and asthma (Vernooy et al. 2013) but there is no studies to 
evaluate the levels of leptin in BPD, in particular the expression in epithelial lung 
fluid. Among non-traditional cytokine it’s possible cite ghrelin, a leptin antagonist 
involved in energy homeostasis, mainly produced by stomach cells, and secondly 
by hypothalamus, pituitary, and other tissues. This peptide is major express in 
digestive system, but low levels were found in nervous system, pituitary but also 
in lung (Ghelardoni et al. 2006). Studies about ghrelin tested the role on 
metabolism and food intake (Mokrosiński and Holst, 2010)	 and role in 
inflammation (Dixit et al. 2004) but there are no studies about the putative link 
with BPD. The finest non-invasive and first-step-method to test the presence of a 
molecule in lung is the EBC collection. To the best of knowledge, the main 
limitation in the analysis of EBC is the missing of standardized protocols to 
support validation studies (Hovàrt et al. 2005). EBC is obtaining by cooling 
exhaled air into a system of sample tube maintained at low temperature, below 
water freezing point. In our study, just after mechanical ventilation the sample 
collection was kept with the procedure described by Hunt in 2002 (Hunt, 2002), 
and the sample condensing into test tube. Correct preservation of sample integrity 
depends on the maintaining of constant temperature, avoiding thermal excursion. 
In our ventilated circuit, the tube begins from medical ventilator, but its length 
was too much extensive if compared with a exhaled kit for sample collection, 
recommend in guidelines for collaborative patients (Hovàrt et al. 2005). Tubes of 
ventilates newborns can be considered as high death space where the condensates 
compounds can partially destroy, leading to lack of sample quality. Probably for 
this reason in this procedure applied to children underwent to mechanical 
ventilation, we not found levels of leptin and ghrelin in EBC sample. Moreover, to 
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avoid a possible sample bias the EBC collection started just after clinical 
stabilization and the sample was collected only in the first day of intubation. The 
collection after several days of intubation can’t be scheduled, because clinical 
conditions lead to extubate infants in different time point, with results difficult to 
compare. In literature is well described how these infants show a premature lung 
development, but according to our time point, the lung injury is probably not 
enough markedly expressed to be evaluated with presence of leptin and ghrelin in 
condensate of epithelial lung fluid. On other hand, it is possible that leptin and 
ghrelin may not be predictive markers of lung injury. This supposition is 
supported by fact that we have collected the sample too prior with respect the 
possible development of BPD. This finding suggest how improve sample 
collection, avoiding every possible confounder involved in physical, but also 
molecular integrity of each sample. Moreover, it's necessary to better define the 
time point setting and research best period, during the mechanical ventilation, 
where is better collect the sample. Nevertheless, a non-invasive approach well 
integrated in clinical practice was showed efficacy to collect sample of EBC in 
ventilated infants, because clinical parameters were unchanged during the sample 
collection, and not influenced negatively the prognosis of clinical stabilization 
after preterm birth. As described before, EBC should be considered bio-fluid of 
great interest for research in clinical analysis, but there is a need in the 
standardization of EBC collection used for evaluating mechanical ventilated 
infants, because this field is still relatively limited for practical applications. 
Moreover, the present approach has demonstrated how collect EBC from 
ventilated infants and children is possible and safe, but also is needed 
commercially available hardware to collect the sample and preserve it from 
degradation. Self-made collectors can’t afford to establish standards procedures 
and doesn't allow data comparison from different sampling, because doesn't give 
setting up the correct temperature and duration of collection. Failure presence of 
leptin and ghrelin in EBC, as previously described, suggests they probably aren’t 
early markers of BPD and for this reason we assessed the expression of leptin and 
ghrelin in the lung of animal model of BPD. In literature are showed several 
studies on BPD, first with neonatal mice (Bonikos et al. 1976) and studies that use 
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rat BPD employed high oxygen concentration (60%) (O'Reilly and Thébaud 
2014). Hyperoxia induced neonatal lung injury model has found a large use in 
animal model of BPD because it is easy program the birth, they have a large pups 
size in only 21 days of gestation. Regarding the lung, most rapid rate of alveolar 
development occurs between 3 to 8, and is almost ended by the day 14. Although 
rats born in this particular stage of lung development, their lungs are functionally 
fully developed and no requires, as in human, specific intervention to stabilize 
clinical conditions. After birth and exposure at high levels of oxygen in this period 
produces anatomical and functional changes in the lung (Thurlbeck, 1975) 
(Meyrick and Reid, 1982). The induced lung injury is similar to those seen in 
preterm newborn that has developed BPD. Moreover, we have extended the 
period of hyperoxia demonstrating that the morphological changes in 
alveolarization occur in the first days of life and the outcome is designed in this 
period. Although it has been extended period of hyperoxia, the minimal 
expression of ghrelin and leptin in lung tissue level does not changed. Conversely 
to the sample collected in the first day of life in infants ventilated, in this 
experiment the BPD was induced, and according to several studies with hyperoxia 
treatment it's possible obtaining an animal with lung development very similar at 
human BPD. Nevertheless, a minimal expression of leptin and ghrelin was found 
in lung tissue of BPD and this data is no significantly different if compared with 
control group. The finding probably confirm also the negative answers obtained 
with ELISA assay. In fact, also in this measures, no levels of leptin and ghrelin in 
EBC were discovered. In our study the most impressive results of treatment with 
60% of oxygen concentration was the body development, and this is partially in 
concordance with other studies reported by O'Reilly in a recent review (O'Reilly 
and Thébaud 2014). In fact, important differences on body weight in control and 
BPD group were found, but also an evident hair suffering. Hyperoxia group 
presented body characteristics worse than control group kept room air, and 
significant differences were found in trachea caliber of two groups. In particular, 
hyperoxia group presented a high caliber than control group suggesting how, for 
these animals, the treatment was weighty in respiratory conditions. In the current 
study we demonstrated that prolonged exposure to high oxygen concentration 
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(PN14) lead to lung injury very similar to those presents in infants with BPD, and 
moreover a continued exposure to high oxygen concentration (PN28) shows an 
increase in inflammatory and pulmonary edema response. In next future we will 
test our sample with a screening of proteomic and metabolomics features, and 
identify putative markers of early develop od BPD during the ventilation and 
oxygen support. Additionally, is necessary to focus and standardize the sample 
collection, with particular attention on the hardware, because methodology at the 
end of ventilated circuit is not able to reduce the risk of sample contamination or 
sample degradation. This is an important point and suggests that the temperature 
of sample tube and in the collect circuit are probably a key points where is 
required to refine the methods. Even if in the current study a specific role of leptin 
and ghrelin remain to be clearly established, and the expression of these two 
hormones in lung of animal model of BPD was not strongly expressed, is 
necessary to further investigate these two markers and probably focus the 
attention on metabolic part, that remains the main role of these two hormones. In a 
recent work Merigo and colleagues (Merigo et al. 2016) described how molecules 
implicated in glucose homeostasis are differently express in airways of rats. Next 
future could provide new details in airways of animal model of BPD, to better 
understand the complex functions and putative implication of energy homeostasis. 
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LIST OF ABBREVIATIONS 
ADMA  Asymmetric Dimetilarginine 
BAL  Broncho Alveolar Lavage 
BMI  Body Mass Index 
BPD  Bronchopulmonary Dysplasia 
BSA  Bovine Serum Albumin 
COPD  Chronic Obstructive Pulmonary Disease 
EBC  Exhaled Breath Condensate 
ELISA  Enzime Linked Immuno Sorbent Assay 
GERD  Gastro Esophageal Reflux Disease 
GH  Growth Hormone 
GHS-R  Growth Hormone Secretagogue Receptor 
GSH  Glutathione 
H&E  Hematoxylin and Eosin 
HHFNC  Heated High-Flow Nasal Cannula  
HIV  Human Immunodeficiency Virus 
HRP  Horseradish Peroxidase 
ICAM-1 Intercellular Adhesion Molecule 1 
IL-1  Interleukin 1 
IL-10  Interleukin 10  
IL-1β  Interleukin 1 β 
IL-6  Interleukin 6 
IL-8  Interleukin 8 
Interferon- γ Interferon gamma 
JAK  Janus Kinase 
MMP  Matrix Metallo Proteinase 
NF-kB  Nuclear Factor Kappa B 
PBS  Phosphate Buffered Saline 
PGE  Prostaglandin 
PGHS-1 Prostaglandin-endoperoxide synthase 1 
PGHS-2 Prostaglandin-endoperoxide synthase 2 
PN  Postnatal days  
PPARγ  Peroxisome Proliferator-Activated Receptor gamma 
RDS  Respiratory Disease Syndrome 
SP-A  Surfactant Protein A 
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SP-B  Surfactant Protein B 
SP-C  Surfactant Protein C 
STAT  Signal Transducer and Activator of Transcription 
TGF1β  Tissue Growing Factor beta 
TH1  T Helper 1 cells 
TH2  T Helper 2 cells 
TMB  Tetramethylbenzidine  
TNFα  Tumor Necrosis Factor alpha 
VEGF  Vascular Endothelial Growing Factor 
 
 
